Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIPUSU: Paclitaxel Liposome vs Gemcitabine in Advanced Squamous NSCLC
NCT02996214Phase 4Unknown
- Sponsor
- Luye Pharma Group
- Start
- Nov 2016
- Primary completion
- Dec 2019
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
Phase 4, randomised, open-label trial of liposomal paclitaxel in squamous cell carcinoma of the lung (SCCL) (2 arms), sponsored by Luye Pharma Group. Primary endpoint: Progression Free Survival up to 2 years. Status: unknown.
02
Drugs
liposomal paclitaxel
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT02996214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02996214.